Stelara's exclusivity strategies, primarily through patent protection and related legal maneuvers, have been instrumental in delaying generic competition. Johnson & Johnson, the manufacturer of Stelara, has employed various tactics to extend its market exclusivity.
How are Stelara's patents structured?
Stelara (ustekinumab) is protected by multiple patents covering its composition of matter, method of use, and manufacturing processes [1]. These patents provide a robust framework for exclusivity, and their expiration dates are staggered.
When does Stelara's main patent expire?
The primary patent protecting Stelara is expected to expire in 2023 [2]. However, additional patents and potential litigation can influence the actual market entry of biosimilars.
Can biosimilars launch before patent expiry?
The launch of biosimilars can be delayed by patent litigation. Companies seeking to market biosimilar versions of Stelara may face challenges from Johnson & Johnson, who may assert their existing patents to prevent or postpone biosimilar entry [3]. Such challenges can lead to lengthy legal battles that extend the period of market exclusivity for the originator drug.
What is the role of patent litigation in Stelara's exclusivity?
Patent litigation is a critical component of exclusivity strategies for high-value drugs like Stelara. Johnson & Johnson may sue companies attempting to launch biosimilars, alleging patent infringement [3]. These lawsuits can result in injunctions that prevent biosimilar sales, effectively delaying competition for an extended period. The outcome of these legal disputes significantly impacts the timeline for generic or biosimilar market entry.
Who are Stelara's potential biosimilar competitors?
Several pharmaceutical companies are developing biosimilars for Stelara. For instance, Amgen has a biosimilar candidate that has faced patent challenges in its path to market [3]. Other companies are also working on their versions, indicating a competitive landscape awaiting patent resolution and regulatory approval.
What are the financial implications of delaying Stelara competition?
Delaying the entry of biosimilars allows Johnson & Johnson to continue generating revenue from Stelara sales without significant price pressure. Stelara is a blockbuster drug, and its exclusivity period is crucial for recouping research and development costs and maximizing profit before generic or biosimilar alternatives become available and drive down prices [4].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/